A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects

This study will seek to enroll immunocompromised patients with lower tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

View full study on ClinicalTrials.gov